| |
GeneSuites is the development manager for Catalyst BioCampus in North Carolina which is on track to support biomanufacturing by 2024. Learn more.
|
|
Today's Big NewsDec 1, 2022 |
| By Annalee Armstrong Roche’s Genentech unit is walking away from a clutch of studies for its leading Alzheimer’s therapy gantenerumab, weeks after the monoclonal antibody failed a pair of phase 3 studies. |
|
|
|
By Kevin Dunleavy The FDA has signed off on Ferring Pharmaceuticals' Rebyota, a one-time, enema-delivered therapy for Clostridium difficile that can restore proper bacterial balance in the digestive system. As the first FDA-approved fecal microbiotica product, Rebyota represents a significant milestone, potentially clearing the way for other such treatments. |
By Robert King A new bill seeks to reform CMS' Medicare coverage determination process in response to criticism of the agency's decision earlier this year to only narrowly cover the drug Aduhelm. |
By Andrea Park Elon Musk may need more press coverage like he needs a hole in the head, but both could possibly be on the horizon for the tech entrepreneur, according to the latest update from his Neuralink brain-computer interface company. |
|
Tuesday, December 6, 2022 | 12pm ET/9am PT Biopharma customers are now demanding that the vendor industry work collaboratively to connect their scientific workflows. This webinar will provide valuable insights for biopharmaceutical scientists, lab directors, IT professionals, and life science vendors. Register now.
|
|
By Gabrielle Masson Eli Lilly CEO David Ricks was confident last year that donanemab would best Biogen’s Aduhelm in a head-to-head battle. Now, the results are in—and Ricks was right. |
By Fraiser Kansteiner Pfizer is plugging 1.2 billion euros into its manufacturing site at Grange Castle in Dublin, where the Big Pharma also plans to add between 400 and 500 new jobs by 2027. The project will “significantly expand” Pfizer's production and laboratory capacity on the Emerald Isle and will bring its overall head count there to around 5,500, the company said. |
By Dave Muoio With one in 10 of the state's hospitals at risk of closure and nearly half logging operating negative margins, the Texas Hospital Association said it's entering the new legislative season seeking pay cut delays, Medicaid expansion and new workforce investments. |
By Conor Hale Traditional MRIs have needed 1,500 liters of liquid helium to run. Philips aims to explore new superconductive materials by working with MagCorp and Florida State University's National High Magnetic Field Laboratory. |
By Annalee Armstrong Prolific biotech maker Roivant and Pfizer have partnered to launch a new inflammatory- and fibrotic-diseases-focused company. We checked, and Roivant is not ready to publicly name the new venture, but we at Fierce have a suggestion that rolls off the tongue: Pfvant. |
By Paige Minemyer Highmark Health posted a $268 million net loss through the first nine months of 2022 as multiple headwinds drag its finances. |
By Angus Liu GSK's emerging oncology business just got a much-needed boost after several recent setbacks. A first glimpse at its PD-1 inhibitor's head-to-head data against Keytruda looks encouraging. |
By Andrea Park After spending the entire year in a fruitless struggle to return to shareholders’ good graces, Titan Medical is considering a new approach. |
By Zoey Becker Alex Gorsky is set to officially exit Johnson & Johnson. After handing over the CEO position to Joaquin Duato early last year, he will shed his last role at J&J and turn over the board chair position to Duato, who will serve as chairman come January. |
Fierce podcastsDon't miss an episode |
| | This week on "Podnosis," we talk about the rise of virtual care since the pandemic started and what its role will be moving forward. We also discuss some tactics to control rising drug prices in the U.S., like changing PBMs' business model and new companies like the one from billionaire entrepreneur Mark Cuban. |
|
|---|
|
|
|
Tuesday, December 7th, 2022 | 10am ET/7am PT In this presentation we’ll review how we established GOCHO™ cells from an adherent CHO-K1 cell line to meet current industry standards, how the choice of cloning media drove cell culture media choices for the entire cell-line development process, and more. Register now.
|
|
| VideoRevolutionize your monoclonal antibody (mAb) manufacturing with expert insights. Sponsored by: Gibco |
| WhitepaperLearn how to develop a high-performing supply chain for GMP-manufactured chemicals used throughout your biologics workflow. Download the free whitepaper from Thermo Fisher Scientific. Sponsored by: Thermo Fisher Scientific |
| WhitepaperPreparation of critical process liquids and buffer components shifts resources away from core activities and can be filled with inefficiencies and risks that can increase time and costs across your workflow. Learn about the framework to help reduce your total costs beyond capital and operational expenditures and set a solid foundation for successful scale-up of buffer preparation. Sponsored by: Thermo Scientific Production Chemicals and Services |
| Webinar Twist Bioscience CSO Dr. Aaron Sato shares how Twist's tools for antibody discovery have been applied to identify antibodies against diverse and challenging targets. See how high-throughput DNA synthesis combined with antibody engineering expertise provides end-to-end antibody discovery solutions. Presented by: Twist Bioscience |
| WhitepaperThis paper outlines how gene therapy supply chains are different from traditional biopharma products, as well as the factors that are essential to success. Sponsored by: Blue Matter |
| Executive Summary Strategies to help scale-up for commercial manufacturing are critical to getting cell and gene therapies to patients as more advanced therapies reach late-stage clinical studies and regulatory decisions. Sponsored by: Catalent |
| WhitepaperHow can Lipid-Based Drug Delivery System help bring poorly soluble drugs to market? Sponsored by: Catalent |
| Whitepaper Download this paper to learn considerations on how to move a biologic through clinical trials faster, advantages of Parallel Processing, and more. Sponsored by: Catalent |
| WhitepaperWhat are key considerations for intranasal delivery in the treatment of acute and chronic conditions? Sponsored By: Catalent |
| WhitepaperLearn how formulation development for a PFS affects manufacturing to drive the industry toward optimizing delivery of injectable products and, ultimately, improving patient care. Sponsored by: Catalent Biologics |
| Research Learn more on an approach for process characterization for the production of a monoclonal antibody, which will improve the efficiency and effectiveness of the process by targeting the right design and number of experiments. Sponsored by: Catalent |
| WhitepaperExplore Catalent’s newest clinical supply facility in Japan, including the comprehensive services & solutions it offers to help support trials both in-country & around the world. Sponsored by: Catalent |
| WhitepaperLearn how Catalent’s extensive network across APAC can meet a wide range of clinical supply needs for sponsors conducting trials within the region. Sponsored by: Catalent |
| |
|
